{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:14:34Z","timestamp":1776057274464,"version":"3.50.1"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.24728","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:58:36Z","timestamp":1632769116000},"page":"e2124728","source":"Crossref","is-referenced-by-count":8,"title":["Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer"],"prefix":"10.1001","volume":"4","author":[{"given":"John","family":"Sharp","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California, Los Angeles (UCLA) Health, UCLA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University, Palo Alto, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"issue":"1","key":"zoi210726r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v70.1","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi210726r2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014.","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"zoi210726r4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi210726r5","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi210726r6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1634\/theoncologist.2016-0476","article-title":"FDA approval summary: nivolumab in advanced renal cell carcinoma after antiangiogenic therapy and exploratory predictive biomarker analysis.","volume":"22","author":"Xu","year":"2017","journal-title":"Oncologist"},{"issue":"19","key":"zoi210726r7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma.","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10189","key":"zoi210726r8","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"zoi210726r9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi210726r10","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced kidney cell carcinoma.","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi210726r11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi210726r12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi210726r13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrclinonc.2017.72","article-title":"Combining drugs and extending treatment: a PFS end point is not sufficient.","volume":"14","author":"Gyawali","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"zoi210726r14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/annonc\/mdy116","article-title":"When is crossover desirable in cancer drug trials and when is it problematic?","volume":"29","author":"Haslam","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi210726r15","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","article-title":"Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration.","volume":"180","author":"Hilal","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"4","key":"zoi210726r16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00432-014-1590-x","article-title":"Failing to improve overall survival because postprotocol survival is long: fact, myth, excuse or improper study design?","volume":"140","author":"Prasad","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"issue":"14","key":"zoi210726r17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi210726r18","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"12","key":"zoi210726r19","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi210726r20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"zoi210726r3","unstructured":"National Cancer Institute. Cancer of the kidney and renal pelvis: cancer stat facts. Accessed April 3, 2021. https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2784532\/sharp_2021_oi_210726_1632146000.98532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:58:42Z","timestamp":1632769122000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2784532"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.24728","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]}}}